Your browser doesn't support javascript.
Immune Predictors of Mortality After Ribonucleic Acid Virus Infection.
Graham, Jessica B; Swarts, Jessica L; Menachery, Vineet D; Gralinski, Lisa E; Schäfer, Alexandra; Plante, Kenneth S; Morrison, Clayton R; Voss, Kathleen M; Green, Richard; Choonoo, Gabrielle; Jeng, Sophia; Miller, Darla R; Mooney, Michael A; McWeeney, Shannon K; Ferris, Martin T; Pardo-Manuel de Villena, Fernando; Gale, Michael; Heise, Mark T; Baric, Ralph S; Lund, Jennifer M.
  • Graham JB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Swarts JL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Menachery VD; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Gralinski LE; Department of Microbiology and Immunology, University of Texas Medical Center, Galveston, Texas, USA.
  • Schäfer A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Plante KS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Morrison CR; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Voss KM; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Green R; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Choonoo G; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Jeng S; Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.
  • Miller DR; Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.
  • Mooney MA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • McWeeney SK; Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.
  • Ferris MT; OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Pardo-Manuel de Villena F; Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.
  • Gale M; OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Heise MT; Oregon Clinical and Translational Research Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Baric RS; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Lund JM; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
J Infect Dis ; 221(6): 882-889, 2020 03 02.
Article in English | MEDLINE | ID: covidwho-27190
ABSTRACT

BACKGROUND:

Virus infections result in a range of clinical outcomes for the host, from asymptomatic to severe or even lethal disease. Despite global efforts to prevent and treat virus infections to limit morbidity and mortality, the continued emergence and re-emergence of new outbreaks as well as common infections such as influenza persist as a health threat. Challenges to the prevention of severe disease after virus infection include both a paucity of protective vaccines as well as the early identification of individuals with the highest risk that may require supportive treatment.

METHODS:

We completed a screen of mice from the Collaborative Cross (CC) that we infected with influenza, severe acute respiratory syndrome-coronavirus, and West Nile virus.

RESULTS:

The CC mice exhibited a range of disease manifestations upon infections, and we used this natural variation to identify strains with mortality after infection and strains exhibiting no mortality. We then used comprehensive preinfection immunophenotyping to identify global baseline immune correlates of protection from mortality to virus infection.

CONCLUSIONS:

These data suggest that immune phenotypes might be leveraged to identify humans at highest risk of adverse clinical outcomes upon infection, who may most benefit from intensive clinical interventions, in addition to providing insight for rational vaccine design.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA Virus Infections / Mortality Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: J Infect Dis Year: 2020 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA Virus Infections / Mortality Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: J Infect Dis Year: 2020 Document Type: Article Affiliation country: Infdis